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Abstract
Drug-eluting stents (DES), which release anti-proliferative drugs into the arterial wall in a
controlled manner, have drastically reduced the rate of in-stent restenosis and revolution-
ized the treatment of atherosclerosis. However, late stent thrombosis remains a safety con-
cern in DES, mainly due to delayed healing of the endothelial wound inflicted during DES
implantation. We present a framework to optimize DES design such that restenosis is inhib-
ited without affecting the endothelial healing process. To this end, we have developed a
computational model of fluid flow and drug transport in stented arteries and have used this
model to establish a metric for quantifying DES performance. The model takes into account
the multi-layered structure of the arterial wall and incorporates a reversible binding model to
describe drug interaction with the cells of the arterial wall. The model is coupled to a novel
optimization algorithm that allows identification of optimal DES designs. We show that opti-
mizing the period of drug release from DES and the initial drug concentration within the
coating has a drastic effect on DES performance. Paclitaxel-eluting stents perform optimally
by releasing their drug either very rapidly (within a few hours) or very slowly (over periods of
several months up to one year) at concentrations considerably lower than current DES. In
contrast, sirolimus-eluting stents perform optimally only when drug release is slow. The re-
sults offer explanations for recent trends in the development of DES and demonstrate the
potential for large improvements in DES design relative to the current state of commercial
devices.
Introduction
Drug-eluting stents (DES) have proven highly effective in reducing restenosis rates relative to
bare metal stents. However, a persistent concern associated with the use of DES is late stent
thrombosis, which can occur up to several years after stent implantation [1–3]. Although its de-
velopment remains incompletely understood, late stent thrombosis is thought to occur as a re-
sult of the delayed healing of the endothelium following its denudation by both the stent and
the balloon upon which the stent is typically deployed. In support of this notion, a recent study
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has demonstrated that DES can in some cases remain unendothelialized five years after stent
deployment [1]. In contrast, bare metal stents are typically covered with new endothelium
within six months of the stenting procedure [4, 5].
Drugs eluted from DES, most commonly paclitaxel or sirolimus, arrest the proliferation of
smooth muscle cells (SMCs) in the arterial wall and hence inhibit vascular restenosis. A likely
reason for the delayed endothelial healing in the case of DES is that these same drugs also in-
hibit endothelial cell (EC) proliferation and migration [6–10] and thus greatly limit endothelial
wound healing. A key question that arises in the design of DES is whether or not it is possible
to deliver anti-proliferative drugs at sufficiently high concentrations to SMCs to prevent reste-
nosis while simultaneously maintaining a sufficiently low drug concentration at the EC surface
to allow sufficiently rapid endothelial wound closure.
We recently developed a computational model for the transport of drugs eluted from DES
within the arterial wall [11]. The model considered the arterial wall to consist of a two porous
layers representing the subendothelial intima and the media. Drug release from the stent was
assumed to occur by diffusion, and drug transport in the arterial wall was assumed to occur by
convection and diffusion with the drug also undergoing a reversible reaction in the media to
represent its binding to SMCs. The baseline model assumed a completely denuded endotheli-
um in the stented portion of the artery, while the endothelium remained intact both upstream
and downstream of the stent. The model was applied to the transport of both paclitaxel and sir-
olimus, and the results revealed important differences between the two drugs in transport char-
acteristics and dynamics. Importantly, the results suggested that drug distribution within the
arterial wall depends on a number of parameters including the drug, its release rate into the ar-
terial wall, and its initial concentration in the stent polymer. These findings serve as the prima-
ry motivation for the present study which focuses on the optimization of drug delivery
strategies from DES for both paclitaxel and sirolimus.
The notion of using optimization in stent design and performance assessment has previous-
ly been invoked in other contexts. For instance, previous studies have reported the optimiza-
tion of stent strut geometry with the goal of minimizing blood flow disturbance in the arterial
lumen [12–15], stresses in the stent itself [16], or stresses in the arterial wall [17]. Pant and col-
laborators recently reported the first attempt at including multiple design objectives and multi-
ple physical phenomena in the optimization process with the use of a steady (time-
independent) transport model to investigate the effect of DES geometric design on the homo-
geneity of drug distribution and its average concentration in the arterial wall [18, 19]. Coupling
a corrosion model to a global optimization strategy [20] Grogan et. al [21] have optimized the
geometric design of the bioresorbable AMS stent (made by Biotronik) to optimize its degrada-
tion performance. In all previous studies, stent geometry served as the design variable. We fol-
low a different strategy and seek to optimize drug release kinetics (elution process) from the
polymer coating as well as the drug concentration initially loaded onto this coating. Release ki-
netics have been at the heart of experimental [22–26] and computational [27, 28] investigations
over the past few years. However, optimal release kinetics remain an open question in the de-
sign process of DES [29, 30]. Optimizing the delivery process of the eluted drug holds the
promise of providing strategies that at least in part address the problem of delayed endothelial
healing.
In the present study, we develop a strategy to identify optimal drug delivery by DES. The
overall goal of the optimization is to maintain an efficacious but sub-toxic drug concentration
in the arterial media while simultaneously targeting minimal drug concentration at the endo-
thelial surface in order to allow stent re-endothelialization. The design variables are assumed to
be the initial drug concentration loaded onto the stent and the drug release rate from the stent
coating. The optimization is implemented by coupling a novel Surrogate Management
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Framework (SMF) optimization algorithm [31, 32] with our physiologically-based computa-
tional model of drug transport in stented arteries (see [11]). This approach is applied to deter-
mine optimal drug delivery strategies for both paclitaxel- and sirolimus-eluting stents. The
results suggest that optimal drug delivery strategies for paclitaxel are very different from those
for sirolimus and that today’s commercial stents are far from optimal.
Materials and Methods
Computational model
Modeling drug transport and reaction in the arterial wall. We have recently described a
computational model for the transport and reaction within the arterial wall of drugs released
by DES [11]. In the present work, we use this model to optimize the elution of the two small hy-
drophobic drugs paclitaxel and sirolimus from DES. Because the model has been described in
detail in our previous work [11], we will only briefly overview it here and highlight its most im-
portant features.
As depicted in Fig 1, the model considers a straight and axisymmetric arterial segment. The
arterial wall is assumed rigid and is modeled as a two-layered structure with the subendothelial
space (SES) of the intima and the media represented as distinct porous layers. The endothelium
and internal elastic lamina (IEL) are considered as interfacial matching conditions, while the
adventitia is modeled as a boundary condition of the media. The model uses a recently devel-
oped reversible second-order reaction model [33] to account for the interaction of the drug
with the cells of the arterial wall. The DES is assumed to consist of three circular cross-section
struts spaced at intervals of 0.7 mm. Each strut has a diameter of 100 μm and is covered with a
10 μm-thick polymer coating, reflecting approximate dimensions of typical second-generation
DES [34]. We assume that as a result of stent deployment, the endothelium is completely de-
nuded within the stented portion of the vessel as well as up to a distance equal to half of the
inter-strut spacing (0.35 mm) both upstream and downstream of the stent but is intact other-
wise. We define the therapeutic domain as the volume of the arterial wall containing the stent
and extending by two-thirds of the stent length both upstream and downstream of the stent
(Fig 1). The flow in the arterial lumen is governed by the Navier-Stokes equations, while flow
in the arterial wall is assumed to be governed by Darcy’s Law. The entire flow field is treated as
steady. Time-dependent drug transport occurs as follows: 1) in the lumen the drug is trans-
ported via convection and diffusion; 2) in the polymer coating of the stent drug transport is as-
sumed to be purely diffusive; 3) in the SES and media drug transport is via convection and
Fig 1. The computational model used in the simulations considers the endothelium to be denuded upstream and downstream of the stent, over a
distance that is one half of the inter-strut spacing measured from the stent strut centers. The subendothelial space and the media are modeled as
distinct layers of the arterial wall.
doi:10.1371/journal.pone.0130182.g001
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diffusion with both specific binding and unbinding of the drug to cells of the arterial wall (ECs
and SMCs) and non-specific binding to the extracellular matrix.
Modeling atherosclerotic arteries. Early atherosclerosis involves EC inflammation and
intimal thickening [35, 36]. Whereas the healthy SES is virtually free of SMCs, the onset of ath-
erosclerosis compromises the IEL and leads to SMCmigration from the media into the SES.
Our previous modeling [11] did not take the presence of SMCs in the SES into account. We
wish to do so here by incorporating a drug reaction term in the SES so that drug transport in
this layer is governed by the following averaged transport equation:
@cses
@t
þ Lses~usesrcses ¼ r ~Dsesrcses
 þ Rses ; ð1Þ
where cses is the superﬁcially-averaged free concentration in the SES (averaging over both
phases of the porous medium containing the pore space and the solid tissue space) and~uses is
the the average ﬂuid velocity in the total volume (matrix plus pores). For the reaction term in
the SES we assume a lower drug maximum binding site density bmax,ses compared to the maxi-
mum binding site density in the media bmax. Moroever, transport of the drug through the SES
is more severely hindered by the presence of SMCs resulting in an altered lag coefﬁcient
Lses ¼ gsesεses, porosity εses and effective diffusivity ~Dses of the drug in the SES relative to the case of
an SMC-free SES. The reaction term in the SES for the bound drug bses is assumed to take the
following form [11, 33]:
Rses ¼
@bses
@t
¼ ð1 εsesÞ1ðkf csesðbmax;ses  bsesÞ  krbsesÞ ; ð2Þ
whereby the maximum binding site density in the SES bmax,ses is calculated as a fraction ξ of the
maximum binding site density in the media bmax. ξ represents the ratio of the volume fraction
of SMCs in the SES to the volume fraction of SMCs in the media and is an adjustable parameter
in the model. kf and kr are the drug binding rate coefﬁcient and the drug unbinding rate con-
stant, respectively.
To model the fact that the IEL becomes damaged as atherosclerosis progresses, we replace
the Kedem-Katchalsky interface condition describing concentration and pressure discontinuity
as used in the original model by a continuous formulation. To obtain the altered transport pa-
rameters (Λses, εses and ~Dses), we apply the method proposed in [37] to the parameter values
used in the non-diseased baseline case as detailed in Appendix 2. In order to allow direct com-
parisons between the baseline model and the case of a diseased vessel, we do not change the
thickness of the SES layer; we assume that stent implantation compresses the diseased intima
to the same extent as the healthy one.
Numerical methods. The governing equations are discretized by means of the finite ele-
ment method using the commercial software package COMSOL Multiphysics 4.3a (COMSOL
AB, Burlington, MA, USA). The tolerance threshold for the relative error of the solution (rela-
tive tolerance) of the momentum equations was set to 10−9. An analysis of the transport prob-
lem showed no change of the solution below a combination of relative tolerance of 10−3 and
absolute tolerance of 10−4. The time advancing scheme is a backward differentiation formula-
tion with variable order and time step size [38]. The maximum time step size is restricted to 1
hour (h). Reducing the maximum time step to one eighth of an hour did not change the solu-
tion, validating our choice for the maximum step size.
The mixed triangular and quadrilateral mesh is enhanced with boundary layer elements at
the interface between the lumen and the arterial wall and at the interface of the stent polymer
coating with the arterial wall. To smoothen the sharp initial condition from the stent polymer
Optimization of Drug Delivery by Drug-Eluting Stents
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to the surrounding domain, the inner boundary of the triangular polymer mesh is enhanced
with boundary layer elements, with the initial condition transitioning from c(t = 0) = 1 to c
(t = 0) = 0 using an infinitely differentiable step function. The classical approach of a mesh in-
dependence study [39] was used to determine the number of elements in the lumen, the SES
and in the polymer. More specifically, we successively increased the number of mesh elements
in each of these layers by a factor of 1.5 to 2 until the time evolution of the average concentra-
tion in the SES and the polymer showed a relative difference of less than 1% from one mesh it-
eration to another. Similarly, we used the average wall shear stress along the lumen-wall
interface and the flow profile downstream of the stent as the test quantities to verify grid inde-
pendence in the lumen. In the media, however, the maximum cell size was limited by the oc-
currence of spurious oscillations in the solution. This resulted in an overall very fine mesh with
approximately 290 000 elements. Computation time for one simulation performed on 2 cores
of an Intel Xeon CPU X5680 @ 3.33GHz processor was approximately 2 h.
Time scales and dimensionless quantities for drug transport. In order to better interpret
the results, it is useful to recall dimensionless quantities characterizing the transport problem
(see [11] for details):
• Peclet number (Pe): ratio of diffusion time scale to convection time scale,
• Damköhler number (Da): ratio of diffusion time scale to binding time scale,
• and the ratio of the former two dimensionless quantities DaPe: ratio of convection time scale to
binding time scale.
The values of these parameters used in the current simulations are given in Table 1 for both
paclitaxel and sirolimus. A time scale that is not accounted for by these dimensionless quanti-
ties is the drug unbinding time scale, which is also shown in Table 1.
The major difference between the two drugs lies in the relative importance of convection
compared to reaction: sirolimus’ binding rate is so high that it even dominates the convective
transport (Da
Pe
 1), whereas paclitaxel is more sensitive to convection (Da
Pe
< 1). We can also see
that drug unbinding from binding sites in the media occurs significantly more slowly for pacli-
taxel than for sirolimus. For both drugs, the unbinding time scale is the slowest time scale in
the transport problem.
Optimization formulation and methodology
Cost function. We formulate a cost function that needs to be minimized for optimal drug
delivery from DES. Minimization of the cost function serves to accomplish the following two
principal objectives:
1. Therapeutically efficacious but sub-toxic drug concentration in the media: The eluted drug
needs to have its desired therapeutic effect. We assume that as long as the local drug concen-
tration in the media remains within the drug’s therapeutic window, i.e. above an efficacious
minimum threshold and below a toxic maximum concentration, the drug effectively arrests
Table 1. Drug unbinding time scale and dimensionless quantities for the stented part of the media for paclitaxel and sirolimus.
Drug Unbinding time (h) Peclet number Damköhler number Damk€ohler number
Peclet number
Paclitaxel 210.7 13.0 6.75 0.5
Sirolimus 11.2 3.7 125.0 34
doi:10.1371/journal.pone.0130182.t001
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SMC proliferation thereby having the desired effect of preventing neointimal hyperplasia
and vascular restenosis.
2. Minimal drug concentration at the arterial wall luminal surface: We need to minimize drug
concentration at the luminal surface in order to allow endothelial wound healing to occur.
We postulate that if the drug concentration at the luminal surface remains below the lower
limit of the drug’s therapeutic window, then EC proliferation will be unhindered.
How well a particular stent design performs in accomplishing the two objectives described
above can serve as a metric of the quality of the design. For the purpose of the current investi-
gation, a design is defined by the two parameters that determine the drug delivery strategy
from DES: the initial drug concentration c0 in the stent polymer coating and the characteristic
drug release time from this polymer coating. Because drug release is assumed to occur by diffu-
sion only, this characteristic time is given by tE ¼ pL
2
c
ð4DcÞ [40, 41], where Lc is the thickness of the
polymer coating and Dc is the drug diffusion coefficient in the coating. The two parameters de-
fining a particular design serve as input for a simulation using the computational model de-
scribed in the previous section. The resulting concentration distribution is then used as the
basis to quantify the performance of a particular design by means of the following cost func-
tion:
JETBðc0; tEÞ ¼ Im þ
1
3
ðT l þ T ses þ TmÞ þ Bm : ð3Þ
In Eq (3), the cost function JETB is formulated as the sum of three scores evaluated within the
therapeutic domain of the numerical model: a score that denotes drug inefﬁcacy in the media
(Im), an overall toxicity score that consists of the arithmetic average of the three toxicity scores
in the lumen, subendothelial space (SES), and media (T l, T ses and Tm, respectively), and a buff-
er score (Bm). The shape of the resulting score sheet of the cost function JETB is schematically
depicted in Fig 2 (solid line). We will now describe the three scores that constitute the score
sheet of the cost function in detail.
Fig 2. Shape of the score sheet for the cost function at the endothelium (dashed line) and in the media
(continuous line).
doi:10.1371/journal.pone.0130182.g002
Optimization of Drug Delivery by Drug-Eluting Stents
PLOS ONE | DOI:10.1371/journal.pone.0130182 June 17, 2015 6 / 29
The inefficacy score in the media Im is defined as follows:
Im ¼
1
Vm;th
Z
Vm;th
φ dV where φ ¼
(
1; if cT;m  ceff ;
0; otherwise:
ð4Þ
Every point in the medial portion of the therapeutic domain with a drug concentration below
the minimum efﬁcacious threshold ceff is assigned a score of 1 and a score of 0 otherwise. The
inefﬁcacy score Im is obtained by integrating the point-by-point scores over the entire medial
therapeutic domain volume (Vm,th) and then dividing by this volume. Therefore, Im represents
the percentage of the medial volume within the therapeutic domain where the total drug con-
centration cT,m (i.e. sum of free and bound drug) falls below the minimum efﬁcacy threshold.
Eq (4) is evaluated for every time point of the simulation and then averaged over the entire sim-
ulation time tend yielding the time-averaged inefﬁcacy score Im. The simulation time tend corre-
sponds to the period of time over which the optimization is performed.
While the minimum efficacious concentration ceff sets the lower limit of the drug therapeu-
tic window, the toxic concentration ctox defines the upper limit. In the media, the toxicity score
Tm is obtained through the following series of steps. First, similar to the inefficacy parameter,
the expression
Wm ¼
1
Vm;th
Z
Vm;th
W dV where W ¼
cT;m  ctox
gthrctox
; if cT;m  ctox;
0; otherwise:
ð5Þ
8><
>:
is evaluated. This integral quantiﬁes the fractional volume of the media within the therapeutic
domain that is exposed to toxic drug concentrations, with the score weighted by the relative de-
viation from the toxic threshold so that the higher the concentration above the toxic threshold,
the higher the score (and hence the larger the penalty). The scaling factor γthr provides a mech-
anism for adjusting the weighting to establish which deviation from the toxic threshold is con-
sidered equally harmful as a concentration that is below the efﬁcacious threshold (i.e. a score of
1). Once this ﬁrst step is completed, the second step consists of mapping the result of Eq (5)
onto a hyperbola whose asymptote is at the limit value ϑlim:
Tm ¼
1þ Wlim  Wthr
Wlim  Wm
Wm
Wthr
; if 0  Wm < Wlim;
1; otherwise:
ð6Þ
8><
>:
The slope of this hyperbola is adjusted such that it passes through 1 at the threshold value ϑthr.
Furthermore, the hyperbola is lifted by 1 to emphasize that any toxic concentration is undesir-
able. The rapid increase in toxicity score as drug concentrations increase above the toxic
threshold underscores the notion that these concentrations should be avoided by all means and
serves to drive the optimization away from these concentrations.
The arterial wall luminal surface is handled virtually identically to the media with the fol-
lowing two equations:
WS;l ¼
1
Sl;th
Z
Sl;th
WS dS where WS ¼
cl  ceff
gthrceff
; if cl  ceff ;
0; otherwise:
ð7Þ
8><
>:
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Tl ¼
1þ Wlim  Wthr
Wlim  WS;l
WS;l
Wthr
; if 0  WS;l < Wlim;
1; otherwise:
ð8Þ
8><
>:
There are two differences to point out: 1) Given that we are now considering the lumen-wall in-
terface, the integral in Eq (7) becomes a surface integral rather than a volume integral. 2) At
the luminal surface we do not want the drug to impair EC proliferation; therefore, we consider
that the “toxic” concentration limit is the minimum efﬁcacious concentration and formulate
the toxicity score in a manner to drive the algorithm towards concentrations lower than this
threshold. We note that because a concentration jump occurs across the luminal surface when-
ever endothelium is present, we evaluate the interfacial toxicity parameter from both the lumi-
nal side (denoted by ϑS,l and Tl) and the SES side (denoted ϑS,ses and Tses). The SES evaluations
are similar to those shown above for the lumen but with the concentration cl replaced by cses.
The arithmetic mean of the toxicity scores from the luminal and SES sides provides the toxicity
score of the luminal surface Te. As in the case of the inefﬁcacy score, the toxicity scores are eval-
uated for every time point of the simulation and then averaged over the entire simulation time
tend. The resulting score sheet of the cost function at the luminal surface is schematically de-
picted in Fig 2 (dashed line).
The final term appearing in the cost function is the buffer score Bm which is defined as fol-
lows:
Bm ¼
1
Vm;t
Z
Vm;t
b dV where b ¼
cT;m  ctol
ctox  ctol
; if ctol  cT;m < ctox;
0; otherwise:
ð9Þ
8><
>:
The portion of the therapeutic domain of the media with a concentration superior to a tolerable
value ctol but inferior to the toxic threshold ctox is weighted on a scale that increases linearly
from 0 to 1 as the drug concentration approaches ctox. The spatially-averaged Bm is then aver-
aged over the simulation period tend to form the ﬁnal buffer score Bm.
The primary purpose of Bm is to create a buffer region in the optimization by penalizing
concentrations close to the toxic limit ctox. The value of ctol ensures a certain robustness of the
optimization, in the sense that optima that are immediately adjacent to non-optimal regions
can be avoided. In addition to this role, the tolerable concentration ctol also drives the optimiza-
tion towards designs with a more spatially homogeneous drug distribution in the arterial wall.
Designs that lead to concentrations that lie within the reduced concentration window bound
by ceff and ctol have a smaller concentration variation and are thus more homogeneous. They
are favored over less optimal designs with concentrations that lie between ctol and ctox.
Choice of cost function parameters. The cost function described above provides a set of
calibration parameters that offer flexibility in balancing the relative importance of efficacy vs.
toxicity. While the two concentration thresholds ceff and ctox need to be determined experimen-
tally, the remaining four parameters ctol, γthr, ϑthr and ϑlim allow calibration of the stringency of
the toxicity constraint. Thus, it might be deemed acceptable to live with a certain level of wall
toxicity in some cases but not in others, and these adjustable parameters allow this form of fine
tuning. In light of the severe consequences of delayed endothelial healing [42, 43] and in view
of currently available experimental data, we chose the calibration parameters summarized in
Table 2.
The choice of parameter values for ctol, γthr, ϑthr and ϑlim is rather conservative and is ex-
pected to allow us to avoid arterial wall toxicity. Lacking experimental data on the relative
Optimization of Drug Delivery by Drug-Eluting Stents
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severity of toxic concentration in the different layers of the arterial wall covered by each toxicity
score, we (arbitrarily) assume the three toxicity scores to be of equal importance. As a conse-
quence, we choose the same set of calibration parameters for each of the toxicity scores and a
weight factor of 1
3
multiplying each toxicity score of the cost function. It should be recognized,
however, that new experimental results or clinical studies might lead to future changes in some
or all of these parameters as well as choosing a different set of parameters for each individual
score.
Both paclitaxel and sirolimus inhibit the proliferation of SMCs and ECs by arresting the
cells at a point in their cell cycle. At sufficiently high concentrations, paclitaxel is cytotoxic and
leads to cell death [7]. Values for toxic paclitaxel concentrations are available in the literature
[23, 44]. The values of minimum efficacious concentration and toxic concentration for pacli-
taxel used in the present work, ceff = 1 × 10
−5 mol m−3 and ctox = 1 × 10
−2 mol m−3, are in agree-
ment with [45]. These values are based on the work of [46] who studied the inhibitory effect of
paclitaxel on cancer cells. This value of the minimum efficacious concentration is in good
agreement with earlier work of [47], who reported prolonged inhibition of human arterial
SMCs growth at a medium concentration of 1 × 10−4 mol m−3 with an IC50 value for paclitaxel
on human arterial SMC growth of 2 × 10−6 mol m−3.
Unlike paclitaxel, sirolimus is a cytostatic agent, i.e. its arrest of the cell cycle is not associat-
ed with cell death even at a relatively elevated concentration [7]. This behavior allows for a
wider therapeutic window for sirolimus than for paclitaxel. [48–50]) all report IC50 1 × 10−6
mol m−3 for human SMC proliferation and/or migration. This is of the same order of magni-
tude as the IC50 value for paclitaxel for human arterial SMC growth. We thus set the value of
the minimum efficacious concentration for sirolimus to ceff = 1 × 10
−5 mol m−3, which is the
same value as that for paclitaxel. The toxic threshold of sirolimus is less clear, and only limited
toxic reactions to sirolimus have been reported [51, 52]. We thus set the toxic concentration
threshold to 200% of the maximum binding site density of sirolimus. These threshold values
for the baseline case are summarized in Table 2. In order to study the effect of these threshold
choices on our results, we will also present results for a case where these thresholds were multi-
plied or divided by a factor of 10. The effect of total drug dose (integral of drug concentration
over time) is not considered as a separate metric in the present cost function because the exper-
imental evidence in the literature of the effect of drug dose is too sparse to be translated into a
reliable metric.
Practical considerations. To avoid spending valuable calculation time on undesirable pa-
rameter configurations, we implemented additional criteria terminating the evaluation process
of the cost function if the toxicity parameter ϑm surpasses a value of 5% or if the maximum
total concentration in the media cT,m drops below the efficacious limit at any time after day 5
of simulated time. The latter criterion automatically discards designs that do not lead to effica-
cious concentration levels within that five day period. If the simulation is terminated early, we
take the score calculated at the last computed time point prior to termination as the basis value
for the remaining time points in the averaging process. The toxicity parameter was capped at a
Table 2. Calibration parameters of the cost function.
Drug ctol γthr Wthr Wlim ceff (mol m−3) ctox (mol m−3)
Paclitaxel 90%  ctox 1% 1% 5% 1 × 10−5 1 × 10−2
Sirolimus 90%  ctox 1% 1% 5% 1 × 10−5 0.73
doi:10.1371/journal.pone.0130182.t002
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maximum value Tmax = 10, since this already corresponds to a ten-fold increase over what by
design would be considered an undesirable situation.
To impose a gradient in the case of non-efficacious designs, we add the quantity
1 maxðcT;mÞ
ceff
h i
to Im. Based on typical DES release times and motivated by the pathobiology fol-
lowing stent implantation, we set four weeks as the target simulation time tend [53–56]. A sensi-
tivity study of the cost function has shown that our results are fairly insensitive to a variation of
the evaluation period between one and eight weeks.
To keep the simulation time of each function evaluation to a minimum and as has already
been mentioned, we only include three stent struts in our numerical model. Thus, the overall
stent length simulated is considerably smaller than real stents. Our simulations have shown
that, with the exception of the first and last strut, the concentration distribution around the
struts within the arterial wall is symmetric and almost identical around the central struts [11].
Since this concentration distribution serves as the basis for the evaluation of our cost function,
we can approximate a longer stent by appropriately multiplying the score obtained for the sym-
metric mid-section of our strut setup. A sensitivity analysis has revealed that the final results
are only minimally sensitive to this form of stent elongation.
Optimization framework. We use a SMF-type optimization algorithm [57] to minimize
the cost function JETB. Here we will only outline the basic concepts of this method. The reader
is referred to [31] for more details.
The SMF method belongs to the class of pattern search algorithms for numerical optimiza-
tion. These algorithms minimize a given cost function by gradually exploring the space of pos-
sible designs. In our case, each combination of drug concentration initially loaded onto the
stent c0 and drug release time tE constitutes a point in the design space.
Booker et al. (1999) [57] introduced the idea of a global search step that efficiently leverages
information obtained from previously evaluated points of the design space. All previously eval-
uated points are used to create an approximation of the cost function hypersurface which
serves as an inexpensive surrogate to scan for and identify potential new minimum points in
the entire design space. As long as the potential minimum points revealed by the search step
yield improved cost function values, the information from these points is added to the approxi-
mation surface and a new search is performed.
The most common interpolation method used in this context is the Kriging method [58, 59].
A major advantage of this interpolation (and extrapolation) method is that on top of an estima-
tion of the function value, it also provides the level of uncertainty in the estimated value (Fig 3).
This information can then be used to enhance the search procedure: instead of minimizing the
Kriging interpolant directly, new prospective optimum points are identified by maximizing the
probability of improvement over the current optimum by a predefined margin [20].
The optimization procedure (Fig 4) begins with the evaluation of a set of initial sampling
points to create the very first surrogate surface. We use the latin hypercube sampling algorithm
presented in [60] to ensure a uniform distribution of these points throughout the design space.
We use 20 initial designs for our 2-dimensional design space.
When a search step fails to yield a new minimum, a poll step is initiated. Starting from the
current minimum point of the design space, a set of new points is chosen in the design space.
The choice of these points is restricted to a grid which discretizes the design space and defines
the search pattern. The cost function values at these points are then evaluated (a process re-
ferred to as polling). If any one of these points yields a cost function value that is lower than the
value associated with the initial point, then this point becomes the new minimum point. If, on
the other hand, none of these points is able to improve the cost function, then the grid spacing
is refined and a new set of points is chosen on this new grid. A new search step succeeds the
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poll step, independent of its outcome, taking into account all newly evaluated designs and their
respective computed value of the cost function. We consider the design space to have been
fully explored once the mesh of the poll step is refined 10-fold, all points neighboring the cur-
rent minimum point have been polled, and the search step fails to identify new optimum points
in five consecutive search steps. At this point the optimization is terminated.
The following two key novelties have been implemented in the present SMF algorithm lead-
ing to improved performance of the optimization procedure: 1) The arrangement of different
designs in the design space is on a grid with a higher number of directly neighboring designs
than in the case of the typically used Cartesian grid [14, 61–64]. Search and poll steps are al-
ways performed on a “laminated” lattice [31], which maximizes the regularity and density of
the grid points for the respective dimension of the design space. 2) The factor by which the grid
is refined after a failed poll step is reduced compared to other algorithms so that the number of
designs that can be investigated in each poll step increases without having to pick designs that
are very close to the current optimal point (see Fig 5). This new mesh adaptive direct search
(MADS) algorithm is dubbed “λ-MADS” [31].
Optimization cases and performance
We will present a total of 12 different optimization runs. To generate each detailed map of the
cost function as presented in the following section requires approximately 10 days using a total
of 8 cores of an Intel Xeon CPU X5680 @ 3.33GHz processor. However, the algorithm permits
identification of the optimal region after 3 days. The additional week is required to refine the
initial cost function map.
The optimization results are divided into two groups: the first group addresses the optimiza-
tion of the drug release strategy for paclitaxel and sirolimus assuming the baseline values for
the efficacy and toxicity threshold and investigates the effect of varying these thresholds on the
Fig 3. One-dimensional example of a Kriging interpolation hypersurface (red) of the true cost function
hypersurface (black) based on 10 evaluated points P (green) with uncertainty s (blue) over the design
space x. The design space x and the cost function values form the cost function hyper-space. The true cost
function minimum (green cross) could be almost perfectly identified by the Kriging model (predicted minimum
marked by red circle) with only 10 points.
doi:10.1371/journal.pone.0130182.g003
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optimization results; the second group investigates the effect of an increasing SMC fraction in
the SES on the optimal drug release strategy for paclitaxel and sirolimus.
Results
We wish to determine the optimal drug delivery strategy, defined here as the combination of
the drug concentration initially loaded onto the stent c0 and the drug release time tE as
Fig 4. Flow diagram of the optimization algorithm and its coupling to the computational model.
doi:10.1371/journal.pone.0130182.g004
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characterized by the diffusion coefficient of the drug Dc within the 10 μm-thick polymeric ma-
trix in which it is embedded. The optimization is performed for both paclitaxel and sirolimus.
Physical insight into the effect of release kinetics on arterial wall drug
concentration
Before describing the optimization results, we will focus on three concrete examples of pacli-
taxel release strategies and their resulting drug concentration distributions (Fig 6). This allows
us to gain some physical insight into the optimization results.
Fig 6A shows the time evolution of the percentage of the remaining drug mass in the poly-
mer coating resulting from three different release kinetics. The first column depicts release ki-
netics where all of the drug contained in the polymer is released within the first few hours
following DES implantation, i.e. in a quasi-bolus fashion. The stent emptying time scale tE is
significantly shorter than either the time period considered in our simulations (4 weeks) or the
largest time scale in the transport problem, namely the drug unbinding time. In the second col-
umn, drug release occurs over a period of one month, which is comparable to the drug unbind-
ing time scale so that drug release rate becomes concentration-dependent. We will denote
these release kinetics as first-order. In the third column, the drug is released so slowly that
most of the drug is not released during the 4-week period considered. Drug release occurs at a
Fig 5. Polling the design space. A: Two consecutive factor of 4 grid refinements and factor of 2 shell of prospective polling points refinements of the
LT-MADS algorithm on a 2-dimensional Cartesian lattice;B: Two consecutive factor of 2 mesh refinements of the λ-MADS algorithm on a hexagonal lattice
A2 with a shell of prospective polling points at a distance of 1, 2 and 3 grid points for the initial grid (k = 0) and after k = 1 and k = 2 consecutive grid
refinements, respectively. Search directions (in blue) of a minimal positive basis connect the current optimum point (in green) with the selected poll designs
(red). Current shell of prospective polling points is marked in red, previous shell of prospective polling points is marked in orange.
doi:10.1371/journal.pone.0130182.g005
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Fig 6. Release kinetics and resulting cost function scores and normalized concentration distributions for repesentative designs of quasi-bolus,
first-order, and zero-order drug release. A: Release profiles as quantified by the time evolution of the remaining mass percentage of drug in the polymer
coating (RMC).B Time evolution of the endothelial toxicity score T e (left y-axis) and the inefficacy score Im (right y-axis). C: Contour plots of the concentration
distribution normalized by the minimum efficacious concentration ceff at 1 hour (first row), 1 day (second row) and 1 week (third row) post stent implantation.
The highest concentration values encountered close to the stent strut surface are colored in black indicating toxic concentrations. A green contour line marks
the threshold between efficacious and non-efficacious drug concentration in the media. If the contour is missing, the entire depicted domain is exposed to
efficiacious concentrations. The red countour lines enclose toxic concentration regions in the media and mark concentration levels at the endothelial surface
that are unacceptably elevated.
doi:10.1371/journal.pone.0130182.g006
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quasi-steady rate with a stent emptying time scale (tE = 5 months) significantly longer than all
other time scales involved in drug transport. We will call this type of release kinetics zero-order
or long-term release.
Fig 6B depicts the time evolution of the endothelial toxicity score and the inefficacy score re-
sulting from the three different release strategies outlined above: tE = 1 h, c0 = 2.5 mol m
−3
(quasi-bolus release), tE = 1 month, c0 = 10 mol m
−3 (first-order release) and tE = 5 months, c0
= 3 mol m−3 (zero-order release). For the quasi-bolus release, we can see that almost immedi-
ately following the beginning of drug release, the toxicity score spikes to the maximum allowed
value of 10 while within the first half hour the media gets flooded with drug at a concentration
leading to efficacious concentration levels throughout the therapeutic domain (very small inef-
ficacy score values). This maximum toxicity score is maintained for the the first two hours
within which the polymer is almost entirely depleted of drug. The toxicity score then gradually
drops to zero within the following 4 hours. The inefficacy score stays at 0.01 throughout the
hours following polymer depletion before eventually increasing as drug is gradually washed
out of the media (not shown in Fig 6B). By the end of the 4-week period (data not shown), the
inefficacy score rises to 0.16 (data not shown).
Similar to the quasi-bolus release, the endothelial toxicity score for the first-order release
immediately spikes to the maximum allowed value. However, contrary to the quasi-bolus case,
the endothelial toxicity score remains at the maximum value until 3.5 weeks after stent implan-
tation and only then begins to rapidly decrease to a value of zero at the 4-week mark. The inef-
ficacy score drops to less than 0.2 within the first hour of release, further decreasing over the
next few hours to 0.02 where it remains for the duration of the 4-week period.
In the case of the zero-order release, the endothelial toxicity score is zero throughout the
considered period, while the inefficacy score drops to 0.25 within the first day of drug release
and attains 0.1 at the 4.5-day mark. The score drops to a minimum of 0.08 within 10 days
and then stays around this value for the remainder of the 4-week period.
Fig 6C depicts the concentration distributions (normalized by the efficacious concentration
threshold ceff) around the stent strut furthest downstream (third strut) at the 1-hour, 1-day,
and 1-week marks for the design points representative of quasi-bolus release, first-order re-
lease, and zero-order release. The quasi-bolus drug release (left column in Fig 6C) leads to the
release of all of the drug within the first few hours after implantation. Accordingly, the highest
drug concentrations are attained within the first hour with local concentrations in the media
near the stent strut exceeding the toxicity limit and unacceptably high concentrations in the
SES (as indicated by the red contour line at the luminal surface). At the 1-hour time point,
drug concentrations are at efficacious levels over practically the entire media. The next two
time points illustrate how the drug concentration decays over the following week. After only
one day, the concentrations at the luminal surface are sufficiently low to allow EC proliferation
and migration. Because the characteristic time for drug release in this case is considerably
shorter than all of the time scales characterizing drug transport and reaction (convection, diffu-
sion, as well as drug binding and unbinding), the quasi-bolus release strategy can be thought of
as a transport-limited case.
For the first-order drug release kinetics (middle column), large parts of the media are al-
ready exposed to efficacious concentration levels at the 1-hour time point (indicated by the
green contour line), whereas the SES experiences drug concentrations that are sufficiently ele-
vated to inhibit EC wound healing (red contour line). After a day, concentration levels in the
media continue to increase, and drug concentration throughout most of the SES remains be-
yond the acceptable level for endothelial wound healing. At the 1-week mark, concentration
levels in the media close to the strut have nearly attained their maximum concentration level of
more than 600 times the efficacious concentration threshold. At the luminal surface, drug
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concentration levels have dropped but are still sufficiently high to inhibit EC proliferation and
migration.
For the zero-order drug release kinetics (right column), the concentrations within the first
hour attain the efficacious threshold in the media only in the vicinity of the stent struts. After
one day, the concentration levels in most of the media are efficacious, except for the zones in
between struts close to the luminal surface. The steady release over the next week slowly in-
creases concentration levels throughout the media leaving almost no zones of the media ex-
posed to non-efficacious concentrations. The highest concentrations observed in the media
close to the struts at the 1-week mark are around 70 times the efficacious concentration thresh-
old. Concentration levels in the SES or at the luminal surface are never sufficiently high to im-
pair EC wound healing. Since all time scales of the transport and reaction problem in the
arterial wall are significantly shorter than the release time scale in this case, this scenario can be
viewed as a quasi-steady state for transport in the arterial wall and hence a release-limited
situation.
Baseline optimization results and their sensitivity to the concentration
thresholds
Fig 7A shows the surface of the cost function obtained using the baseline model setup for pacli-
taxel elution. The plot is the result of a natural neighbor interpolation [65] of the evaluated de-
signs indicated by the gray dots. In analogy to topographical maps (equating function value
magnitude with elevation), we can describe the the cost function as a mountain range with two
valleys that define two optimal regions. We will refer to the directions of increasing concentra-
tions and release time as north and east, respectively. Three colored contours are shown in Fig
7A: the green contour line traces Im ¼ 1 and thus defines the border for inefficacious designs;
the yellow contour line traces Tm ¼ 1 and thus marks the threshold of toxicity in the media;
the red contour line traces T e ¼ 1 and hence demarcates concentrations above which inhibi-
tion of EC wound healing would be expected to occur. It should be noted that the interpolated
surface is only as good as the underlying evaluated designs (indicated by gray dots). Even if this
fact limits our ability to reach detailed conclusions in some local regions of the design space,
the overall conclusions are unaffected.
The optimization results reveal two optimal regions. The first lies in a relatively flat valley
spanning an initial concentration range of 0.6 to 2.5 μg cm−2 and covering a release time of a
few minutes to 4 hours. The cost function score ranges between 0.08 and 0.15 in this valley.
The rapid drug release of these designs causes toxic concentrations in the media and unaccept-
ably high drug concentrations at the EC surface (Tm < 0:01 and T e < 0:06) over very short
periods of time. The second optimal region is in a chasm beginning at a release time scale of
1.5 months and an initial concentration of 1 μg cm−2 and ending at a release time of 12.5
years and an initial concentration of 40 μg cm−2. Designs in this chasm have a cost function
score of less than 0.1. The most optimal designs with a cost function of less than 0.05 lie in a
crevice bounded by the designs tE 5.5 months, c0 4 mol m−3 and tE 1 year, c0 9 mol
m−3. These designs do not lead to any toxicity. Designs in this second region with a cost func-
tion score of less than 1 are bound on the northwestern end by the region of unacceptably high
drug toxicity at the luminal surface (delineated by the red contour line) and on the southeast-
ern side by the zone of unacceptably low drug efficacy in the media (green contour line). It is
interesting to note that designs corresponding to today’s paclitaxel-eluting stents (P-DES) re-
lease the drug over a period of a few weeks to a few months with initial concentration loads
above 10 μg cm−2 [66] and thus lie on top of the central mountain in the north of our
landscape.
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Fig 7B depicts the baseline optimization results for sirolimus elution. The results offer a very
different picture from the case of paclitaxel: there is only a single band of optimal release
(J< 0.05) starting at a characteristic release time of 5 months with an initial concentration
of 1.4 μg cm−2 and ending at a release time of 17.5 years and an initial concentration of
56 μg cm−2. Designs in this chasm do not lead to any toxicity. Similar to the case of paclitaxel,
the band of designs with a cost function score of less than 1 are bounded by the region of unac-
ceptably high drug toxicity at the luminal surface (red contour line) and the zone of
Fig 7. Contour plots of the cost function for paclitaxel (left column) and sirolimus (right column) over the design space consisting of initial
concentration in the stent polymer c0 and release time tE. The scale for the cost function representation is truncated at a maximum of 1; all values larger
than 1 are colored black. The dashed magenta lines in panels A and B mark the time scales for drug unbinding. The green contour line traces Im ¼ 1, the
yellow contour line Tm ¼ 1, and the red contour line T e ¼ 1. The horizontal axis at the top of the plot marks the time points of 1 (h)our, 1 (d)ay, 1 (w)eek, 1 (m)
onth and 1 (y)ear. Gray dots indicate evaluated designs. Optimization cases A: paclitaxel release andB: sirolimus release with baseline cocnentration
thresholds. C: Paclitaxel release andD: sirolimus release with concentration thresholds reduced by a factor of 10. E: Paclitaxel release and F: sirolimus
release with concentration thresholds increased by a factor of 10.
doi:10.1371/journal.pone.0130182.g007
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unacceptably low drug efficacy in the media (green contour line). A yellow contour line does
not appear in this figure because even the highest concentrations considered remain below the
medial toxicity levels. Similar to the case of paclitaxel, today’s sirolimus-eluting stents (S-DES)
release the drug over a period of weeks to a few months with initial concentration loads above
10 μg cm−2 [67, 68] and thus lie on top of the central mountain in the north of the landscape.
The results in Fig 7A and 7B were obtained using the baseline values of threshold concentra-
tions for drug efficacy and toxicity. Fig 7C–7F depict the sensitivity of the optimization results
to these threshold values. Fig 7C reveals that decreasing the thresholds for the efficacious and
toxic concentration limits for paclitaxel by a factor of 10 simply shifts the contour lines south-
ward to about 10-fold lower initial concentrations. The principal features that we identified for
the baseline conditions (Fig 7A) remain unchanged: two optimal regions, one in the very fast
release region (release time of a few minutes to 4 h with initial drug concentrations ranging
from 0.1 μg cm−2 to 0.35 μg cm−2) and one in the very slow release chasm (with the most
optimal designs bounded by the two designs tE 4 months, c0 0.2 mol m−3 and tE 4.5
years, c0 2.2 mol m−3). Contrary to the baseline case (Fig 7A), the fast release strategy is
slightly more favorable than the slow release strategy, as demonstrated by the high density of
evaluation points (gray dots) in this region.
Fig 7D shows that a 10-fold decrease in the thresholds for the efficacious and toxic concen-
trations has a similar effect on the optimization of sirolimus release as it does on paclitaxel re-
lease. The principal features of the cost function map remain largely the same with the optimal
stent loading concentrations reduced by approximately an order of magnitude. The most opti-
mal release strategies (J< 0.05) are found in the slow release valley bounded by the two designs
tE 8 months, c0 0.4 mol m−3 and tE 1.5 years, c0 1 mol m−3. The reduced toxicity
threshold in the media leads to the appearance of the yellow contour line that defines a medial
toxicity of T e ¼ 1.
Increasing the thresholds for the efficacious and toxic concentrations leads to a shift north-
ward of the optimal cost function values towards higher initial concentrations. For the release
of paclitaxel (Fig 7E), the most optimal release strategies lie in the fast release valley character-
ized by release times of a few minutes to 4 h at initial concentrations ranging from 10 μg
cm−2 to 35 μg cm−2). Optimal sirolimus release strategies lie in the crevice formed by the two
designs tE 3 months, c0 20 mol m−3 and tE 7 months, c0 35 mol m−3 (Fig 7F).
Sensitivity of the optimization results to smooth muscle cell content in
the subendothelial space
Unlike healthy arteries, atherosclerotic vessels contain SMCs in the SES. The presence of SMCs
in the SES alters drug transport within this layer and necessitates the incorporation of drug re-
action with the SMCs in the SES. Fig 8 depicts the optimization results for paclitaxel and siroli-
mus for progressively increasing fractions of SMCs in the SES, expressed as a percentage of the
SMC volume fraction in the media.
Fig 8A demonstrates that when the SES SMC density is 1% of the medial SMC density, two
optimal zones, a very fast release optimum around tE 1 h, c0 1.9 mol m−3 with a cost func-
tion score of J 0.15 and a slow release optimum in a chasm bound by tE 5 months, c0 3.7
mol m−3 and tE 1.5 years, c0 12.5 mol m−3 with a cost function score J 0.1 exist. The me-
dial toxicity and inefficacy contour lines are basically unaltered compared to the baseline case
(cf: Fig 7A). The endothelial toxicity contour moves slightly southward. To quantify this shift,
we report in Table 3 the approximate c0 on this contour at the four time points tE = 1 h, tE = 1
week (corresponding to the tip of the ridge separating the two optimum zones), tE = 1 month,
and tE = 1 year.
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Fig 8B depicts the results of the sirolimus release optimization assuming an SES SMC densi-
ty of 1% of the medial SMC density. Similar to the baseline case (cf: Fig 7B), we can identify a
single slow release optimum in a chasm bound by tE 3 months, c0 0.9 mol m−3 and tE
4.5 years, c0 11 mol m−3 with a cost function score J 0.1. The medial inefficacy contour
line is basically unaltered compared to the baseline case, whereas the endothelial toxicity con-
tour shifts slightly southward (quantified in Table 3).
Fig 8. Contour plots of the effect of the presence of SMCs in the SES on the cost function for paclitaxel (left column) and sirolimus (right column)
over the design space consisting of initial concentration in the stent polymer c0 and release time tE. The scale for the cost function representation is
truncated at a maximum of 1; all values larger than 1 are colored black. The green contour line traces Im ¼ 1, the yellow contour line Tm ¼ 1, and the red
contour line T e ¼ 1. The horizontal axis at the top of the plot marks the time points of 1 (h)our, 1 (d)ay, 1 (w)eek, 1 (m)onth and 1 (y)ear. Gray dots indicate
evaluated designs. Optimization casesA: paclitaxel release andB: sirolimus release with SES SMC density corresponding to 1% of the medial SMC density.
C: Paclitaxel release andD: sirolimus release with SES SMC density corresponding to 5% of the medial SMC density. E: Paclitaxel release and F: sirolimus
release with SES SMC density corresponding to 25% of the medial SMC density.
doi:10.1371/journal.pone.0130182.g008
Optimization of Drug Delivery by Drug-Eluting Stents
PLOS ONE | DOI:10.1371/journal.pone.0130182 June 17, 2015 19 / 29
When the SES SMC content is increased to 5% of the medial SMC density, the fast release
optimum zone for paclitaxel is reduced more drastically than the slow release optimum zone
(Fig 8C). The optimal fast release strategy has a release time of approximately tE = 1 h at an ini-
tial concentration of c0 0.5 mol m−3 yielding a cost function score of J 0.3. The optimal
slow release crevice is bound by the two designs tE 2 months, c0 1 mol m−3 and tE 5
months, c0 2.3 mol m−3 with a cost function score J 0.15. In the case of sirolimus, the opti-
mal slow release zone shrinks significantly (Fig 8D). An optimal release strategy with a cost
function score of J 0.2 can only be found at tE 2 years and an initial concentration c0 2
mol m−3. The endothelial toxicity contour moves significantly southward for both paclitaxel
and sirolimus as quantified in Table 3.
Increasing the SES SMC content further to 25% of the medial SMC density leaves only a
very narrow area between the endothelial toxicity and medial inefficacy contour lines for both
drugs (Fig 8E and 8F). Optimal designs for paclitaxel under these conditions can be found
along a thin line bounded by tE 14 days, c0 0.19 mol m−3 and tE 2 years, c0 2 mol m−3,
yielding a cost function score of J 0.3. The approximate “initial concentration locations” on
the endothelial toxicity contour are reported in Table 3. When the SES SMC content is in-
creased to 25% of the medial SMC density, the optimal sirolimus release strategy only yields a
cost function score of J 0.5 with tE 1 year, c0 0.3 mol m−3 (Fig 8F). The endothelial toxic-
ity contour moves further southward for both drugs (Table 3).
Discussion
In this paper, we used the Surrogate Management Framework to optimize drug delivery from
P-DES and S-DES. The objectives of the optimization were to obtain drug concentrations in
the media that are efficacious against restenosis but yet are subtoxic, while simultaneously tar-
geting drug concentrations at the EC surface that are sufficiently low so as not to inhibit endo-
thelial wound healing. The two design parameters in the optimization were the drug release
rate from the stent and the initial drug concentration loaded onto the stent. The results re-
vealed dramatically different optimal release strategies for the two drugs, primarily attributable
to differences in the kinetics of their reaction. We now wish to summarize our findings and to
gain insight into the physical basis of the optimization results. Given the assumptions that we
have made and the degree of simplification in our numerical model of drug transport, we will
refrain from denoting one particular combination of design parameters as the optimum and
Table 3. Approximate initial concentration (in mol m−3) at distinct time points on the endothelial toxici-
ty contour line for paclitaxel and sirolimus release strategy optimization.
Paclitaxel tE = 1 h tE = 1 week tE = 1 month tE = 1 year
Baseline 3.5 1 1.9 10.6
1% medial SMC 2.7 0.9 1.85 10
5% medial SMC 1 0.6 1 6.25
25% medial SMC 0.2 0.2 0.35 1.9
Sirolimus tE = 1 h tE = 5 days tE = 1 month tE = 1 year
Baseline 27 1 1.6 8.9
1% medial SMC 11 0.5 0.85 5.7
5% medial SMC 4 0.24 0.28 1.3
25% medial SMC 1.1 0.06 0.1 0.33
doi:10.1371/journal.pone.0130182.t003
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rather focus on a broader description of regions in the design space identified in the
optimization.
Paclitaxel-eluting stents either require quasi-bolus or zero-order drug
release kinetics to avoid adverse concentration levels at the endothelium
Optimization of P-DES led to a design space that is divided into four zones. The first zone is
characterized by initial drug concentrations higher than 10μg cm−2. This zone has no accept-
able designs except for drug release kinetics with a drug release time longer than one year. The
sub-10μg cm−2 area contains the remaining three zones of which only designs with either
quasi-bolus or zero-order release kinetics lead to acceptable outcomes, while any designs with
first-order release kinetics result in undesirable conditions in the arterial wall that are far from
optimal. This conclusion holds regardless of the actual magnitude of the efficacy and toxicity
thresholds.
The simulation results demonstrate that what primarily limits the efficacy of a particular
P-DES design is the excessive supply of drug to the SES, leading to concentrations that are ex-
pected to inhibit EC proliferation and migration. In the baseline computations, we assumed
that the SES was free of SMCs so that drug concentration in the SES is determined by convec-
tion and diffusion only; this leads to lower drug concentrations in the SES than in the case
where SMCs are present in the SES and drug reaction with these SMCs needs to be taken into
account. Given that typical P-DES in clinical use today are loaded with drug concentrations
that are considerably higher than the 10μg cm−2 limit identified here, our results shed light
onto a potential reason for the poor re-endothelialization of P-DES reported in some studies
[69, 70]. Especially notable also is the observation of focal cell necrosis close to stent struts asso-
ciated with high-load P-DES, which is consistent with the present results [66, 71].
Based on the present findings, we propose a number of recommendations for improved
drug delivery strategies from P-DES. The first recommendation would be to lower the initial
drug load by an order of magnitude and to shift the designs to slower release kinetics on the
order of several months or even a year. The combination of the wide therapeutic window of
paclitaxel and its long retention properties ensures sufficient efficacy in the media while the
slow release of the drug precludes adverse concentrations at the endothelial surface even when
SMCs are present in the SES.
The long retention of paclitaxel in the arterial wall also provides a second possible delivery
strategy: quick unloading of the drug within hours thereby flooding the entire wall with pacli-
taxel and then letting arterial wall drug kinetics do the rest. This strategy is largely similar to
the idea of a drug-eluting balloon. If administered at the right concentration and at the right
time frame, the binding process takes up as much drug as is required to provide effective drug
concentration levels in the entire therapeutic domain for weeks. The initial drug concentration
spike is short-lived and should pose no significant problems from the standpoint of re-
endothelialization because the endothelium in the vicinity of the stent struts is severely denud-
ed during the first few days, and the extent of re-endothelialization in the first few days is limit-
ed in any case. Though promising, the outcomes associated with this strategy are expected to
be quite sensitive to changes in the convective field within the arterial wall; therefore, a more
accurate assessment of this field is probably needed before implementation of such a strategy.
Moreover, the presence of SMCs in the SES can limit the success of this strategy. Although the
SMC content in the diseased SES has been reported to be no larger than 5% of the medial SMC
density [72, 73] (and see Appendix 1), in which case this quick release strategy is very promis-
ing, the SMC content is patient-dependent and thus for higher SMC densities the release strate-
gy would need to be tailored to the individual patient.
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A third possibility to address the difficulties associated with paclitaxel is to position the drug
onto the stent in such a manner that it is as far away as possible from the endothelial surface.
An optimization performed with our model where only the abluminal half of the stent poly-
meric coating contained drug (as is done for example on the BioMatrix stent by Biosensors)
demonstrated, however, that this is not sufficient (data not shown). More elaborate designs,
like drug-filled stents where the drug reservoir is inside of the stent body and the drug is re-
leased directly into the arterial wall via small holes (currently developed by Medtronic) or
stents where small drug patches are applied only to the very abluminal surface of the stent
body (similar to the JACTAX HD stent by Boston Scientific) appear to be more promising.
Sirolimus-eluting stents require zero-order release kinetics due to
sirolimus’ short retention in the arterial wall
Aside from the differences in their biological mode of action [7], the most significant difference
between sirolimus and paclitaxel is the factor of 20 that separates their time scales of unbinding
(Table 1). Despite sirolimus’ very high tissue affinity (its lipophilicity is approximately three
times higher than paclitaxel), its short retention in the arterial wall requires a constant supply
of fresh drug from the stent and renders the design of a S-DES with quasi-bolus release kinetics
unfeasible. This sirolimus-specific feature has been reported in the literature [74]. The recent
redesign of the zotarolimus-eluting Endeavour Resolute (Medtronic) stent (zotarolimus is a de-
rivative of sirolimus) is another example highlighting this requirement: the release time was in-
creased from 2 weeks in the initial design to 4 months due to the poor restenosis outcome of
the original design [26, 75].
Time scale restriction aside, it should be noted that the kinetic properties of sirolimus make
it a desirable drug for the design of DES: the high lipophilicity renders transport in the arterial
wall largely independent of changes in the convective field and thus predictable and robust.
Furthermore, initial sirolimus concentration in the stent polymer can be used to tune the con-
centration profile to the requirements of the arterial wall. Additionally, cytotoxicity is less of an
issue for this drug due to its cytostatic mode of action. On the other hand, the lipophilicity of
sirolimus also leads to more pronounced concentration peaks close to the stent struts which
might compromise tissue integrity and explain the increased rate of stent strut malapposition
observed with S-DES [76].
Paclitaxel- and sirolimus-eluting stents with zero-order release kinetics
lead to a similar shape of the cost function
Comparing the contour plots of the cost function for paclitaxel and sirolimus, we can identify
large similarities between the two drugs in the zero-order release kinetics region. In this regime,
the release from the stent coating is quasi-steady and the drug concentration at the stent surface
remains nearly constant over the entire period considered. The time scales of transport and reac-
tion in the arterial wall are all significantly faster than the release time scale so we can assume
that a quasi-steady state is established in the arterial wall. For the case of constant surface concen-
tration or equivalent constant surface flux, strongly lipophilic drugs (like paclitaxel and siroli-
mus) have very similar transport dynamics in the arterial wall that can be categorized depending
on whether or not the applied surface concentration/flux exceeds a well-defined threshold [33].
In the case of above-threshold drug supply, i.e. when the drug concentration in the arterial
wall exceeds the binding capacity of the arterial wall, drug transport is increased since signifi-
cant amounts of drug are now in the mobile unbound state. In the case of sub-threshold drug
supply, drug concentration in the arterial wall is below the binding capacity of the arterial wall,
and drug transport is considerably decreased since the drug is now mostly in the bound and
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thus immobile state. For paclitaxel and sirolimus, this threshold is on the same order of magni-
tude as their respective binding capacities. The cost function requires that drug concentration
throughout the arterial wall remain below the toxic concentration threshold, which in the case
of P-DES and S-DES is below the respective binding capacities. Thus, by design of our cost
function, the optimal slow-release P-DES and S-DES both fall into the sub-threshold category,
hence explaining the similarity of the resulting cost function surfaces in the region of zero-
order release kinetics, where transport dynamics are similar for both drugs.
Paclitaxel vs. sirolimus: a settled debate?
About a decade ago, the FDA approved the first two DES: one eluting sirolimus (Cypher stent
by Cordis) and the other eluting paclitaxel (Taxus stent by Boston Scientific). When we look at
the current generation of DES that are either commercially available or at the clinical research
stage, the initial 50:50 split has shifted significantly in favor of sirolimus and its derivatives to
the point where P-DES appear almost “exotic” [77, 78]. This trend appears to be driven by clin-
ical evidence which often ranks first- and second-generation S-DES ahead of their P-DES
counterparts [1, 3, 79–81]. Another explanation may be the robustness of sirolimus alluded to
above. However, our results offer a potentially different perspective on this issue: the applied
concentrations and associated release kinetics in first-generation P-DES might just have been
unsuited for the kinetics of paclitaxel; note that even though for both drugs the commercial re-
lease strategies lead to a potential inhibition of EC migration and proliferation, in the case of
paclitaxel, but not in the case of sirolimus, toxic concentration levels in the media are also
reached. Other numerical studies (see [11] or [45]) and several experimental studies [23, 66,
70, 71] point in a similar direction.
Consistent with our results, the one-dimensional numerical simulations [45] predict that
initial polymer concentrations that are generally considered quite low can be sufficient to cause
toxic concentration levels in the media and that for commercial concentration levels of 100
mol m−3, toxicity is reached within hours of implantation. Comparing the P-DES at four differ-
ent drug loads (42 μg, 20.2 μg, 8.6 μg and 1.5 μg) in a rabbit model [71] showed an increased in-
flammatory response at the two higher loads compared to the lower loads. The inflammatory
response was attributed to local arterial toxicity of paclitaxel. It should be noted that the 42 μg
drug load is close to the load of the commercial Taxus stent. Not surprisingly, implanting even
higher load P-DES (200 μg cm−2) in a pig model [70] also revealed high levels of arterial in-
flammation leading to adverse structural changes of the arterial wall. Another minipig study
[66] comparing three P-DES with 430 μg cm−2, 145 μg cm−2 (close to the Taxus stent) and
72 μg cm−2 drug loads and reported toxic concentration levels in the arterial wall for the high
load stents. Finally, proliferation assays on human coronary artery SMCs [23] revealed that
paclitaxel loads four to seven times lower than found on Taxus stents can be sufficient to inhib-
it cell proliferation and that a prolonged release strategy of 3 months can be beneficial in terms
of arterial wall toxicity, despite being less efficacious in the first few days after implantation.
Our optimal release strategy results (Fig 7A) are in excellent agreement with the trends of all
these experimental studies. Finally, the recent success of paclitaxel-coated balloons [74, 82–84]
indicates a level of incompletely tapped potential for paclitaxel. Our results demonstrating the
effectiveness of a very rapid release strategy in the case of paclitaxel provide a potential expla-
nation for the success of paclitaxel-coated balloons.
In the present work, we have modeled diseased arteries by incorporating SMCs in the SES.
The results have demonstrated that adding SMCs to the SES shifts the endothelial toxicity con-
tour line towards lower stent loading concentrations since bound drug is now retained in the
SES. Because drug efficacy in the media is unaffected by the presence of SMCs in the SES, the
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performance of a particular drug release strategy becomes a competition between the retention
of the drug in the SES and in the media, where the first has an adverse effect on stent perfor-
mance and the latter a beneficial effect. Therefore, the combination of a high Pe-number
(which leads to faster drug wash-out from the SES) and a long retention time (which provides
higher drug accumulation in the media) render paclitaxel a potentially very interesting drug for
use in DES not only because of the possibility of a fast-release administration mode but also be-
cause it provides greater versatility (compared to sirolimus) in light of the variability in the ex-
tent of SMC content in the SES.
Appendix
Appendix 1. Estimating smooth muscle cell content in the subendothelial
space in an atherosclerotic artery
ξ represents the ratio of the volume fraction of smooth muscle cells (SMCs) in the subendothe-
lial space (SES) χSMC,ses to the volume fraction of SMCs in the media χSMC,m:
x ¼ wSMC;ses
wSMC;m
: ð10Þ
The volume fraction of SMCs in layer j is the volume of SMCs divided by the total tissue vol-
ume of a sample,
xSMC;ses ¼
njVSMC
Vsample
ð11Þ
where nj is the number of cells in a sample volume Vsample and thus,
x ¼ nses
nm
: ð12Þ
[73] determined the medial SMC count per mm2 in atherosclerotic human abdominal aortic
tissue as 2016 cells
mm2
and [72] measured the SMC cell density in human atherosclerotic plaques
as 183 cells
mm2
. Assuming an isotropic distribution of SMCs, we can estimate
x  ðcells=areaÞ
3=2
ses
ðcells=areaÞ3=2m
 3% : ð13Þ
Appendix 2. Changes in the transport equation due to smooth muscle
cell presence
Following the approach in [37], averaging the transport equation in the subendothelial space
(SES) (Eq 1 in the text) with smooth muscle cells (SMCs) yields the following expression for
the lag coefficient:
LSES ¼
Lf ;ses
1 wSMC;ses
ð14Þ
where Λf,ses is the lag coefﬁcient based on ﬁber matrix theory only without SMCs as determined
in [11]. For sirolimus and paclitaxel, this value is Λf,ses = 1.02. Averaging Eq 1 in the text also
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produces a new effective diffusivity in the SES,
~DSES ¼
~Df ;eff ;SES
ð1 wSMC;SESÞf ðwSMC;SESÞ
ð15Þ
where
f ðwSMC;sesÞ ¼
2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 4p wSMC;ses
q arctan 1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
4
p wSMC;ses
q
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 4p wSMC;ses
q þarctan
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
4
p wSMC;ses
q
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 4p wSMC;ses
q
0
B@
1
CA
 p
2
þ 1 4
p
wSMC;ses
ð16Þ
and ~Df ;eff ;SES is the effective diffusivity coefﬁcient from ﬁber matrix theory in the SES as deter-
mined in [11], with a value of ~DPAXf;eff;SES ¼ 1:7 1011m2s1 for paclitaxel and ~DSIRf;eff;SES ¼
1:67 1011m2s1 for sirolimus.
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